drugset / Trial / NCT02803827

Summary

Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have viral gastroenteritis and so not treated with antibiotics - but they may indeed have a treatable cause for their illness. The investigators will conduct a randomized trial to see if rapid testing using novel methods to identify potentially treatable causes of diarrhoea leads to improved outcomes. The investigators will also be randomizing children to Lactobacillus reuteri DSM (daughter strain) 17938 therapy versus placebo (the standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a large multi-centre trial following the previous pilot trial.

Timeline

Start
2016-06
Primary completion
2019-01
Completion
2019-02

Outcome

Missed primary endpoint

paper L. reuteri intervention (mean decrease of 0.07 SD, 95% CI -0.22 to 0.08 SD) on adjusted HAZ at 60 days. PMID 35418412 ↗

paper neither a test-and-treat algorithm targeting enteropathogens, nor a 60-day course of L. reuteri DSM 17938, were found to markedly impact linear growth PMID 35418412 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus reuteri DSM 17938 Other / unclassified 5e+08 unknown Oral

Indications